---
title: "Karyopharm grants 333 RSUs to newly hired employee under inducement plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294732397.md"
description: "Karyopharm Therapeutics granted 333 restricted stock units (RSUs) to a newly hired employee under its 2022 Inducement Stock Incentive Plan. The award, granted on July 31, 2026, vests over three years with 111 RSUs vesting annually, subject to continued service."
datetime: "2026-08-03T20:10:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294732397.md)
  - [en](https://longbridge.com/en/news/294732397.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294732397.md)
---

# Karyopharm grants 333 RSUs to newly hired employee under inducement plan

-   Karyopharm granted 333 restricted stock units to one newly hired employee under its 2022 Inducement Stock Incentive Plan, as amended. \* The award was granted on July 31, 2026. \* Shares vest over three years, with 111 RSUs vesting on each anniversary of the grant date, subject to continued service. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karyopharm Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608031605PR\_NEWS\_USPR\_\_\_\_\_NE16833) on August 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [KPTI.US](https://longbridge.com/en/quote/KPTI.US.md)

## Related News & Research

- [Karyopharm Q2 revenue falls as license revenue drops; expects funds to last into September](https://longbridge.com/en/news/295792100.md)
- [Karyopharm says Phase 3 selinexor maintenance trial in endometrial cancer misses PFS endpoint](https://longbridge.com/en/news/294410278.md)
- [Analyst Reaffirms Buy Rating on Unicycive, Maintaining 12-Month Price Target at $30 After FDA Procedural Setback](https://longbridge.com/en/news/296255704.md)
- [Karyopharm plans August sNDA filing seeking FDA priority review for selinexor-ruxolitinib in myelofibrosis](https://longbridge.com/en/news/294411025.md)
- [Citizens Jmp Reaffirms "Market Outperform" Rating for Allogene Therapeutics (NASDAQ:ALLO)](https://longbridge.com/en/news/296112335.md)